| Patient | Emily Dickinson |
|---|---|
| Date of birth | 1830-12-10 |
| Identifiers | MRN HR-NI023-SYN-TD; SSN (made up) 000-23-6081 |
| Document date | 2026-11-01 |
| Author | Lucinda Hartwell, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care home visit for headaches, nausea, and tiredness, with raised blood pressure and abnormal kidney tests. Concerns: Headaches, nausea, and tiredness for several months, worse in the mornings; Wants her care at home or by video, with as few trips to the clinic as possible. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Naproxen sodium 220 mg oral tablet, two tablets by mouth as needed for headache (over the counter) | Two tablets as needed, up to twice a day | Oral route | 1884-10-01 to 1885-01-12 | stopped | S |
| Losartan 50 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1885-01-12 to 1885-02-02 | completed | S |
| Losartan 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1885-02-02 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1885-01-12 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1885-01-12 | active | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day | Two tablets every 6 hours as needed; maximum 6 tablets a day | Oral route | 1885-01-12 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1885-02-02 | active | S |
| Amlodipine 5 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1885-03-02 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| 12-lead electrocardiogram at the home visit: sinus rhythm, borderline voltage criteria for left ventricular hypertrophy | 1885-01-12 to 1885-01-12 | completed | S |
| Kidney ultrasound: right kidney 10.1 cm, left 10.3 cm, with mildly increased cortical echogenicity; no hydronephrosis, stones, or cysts; bladder normal | 1885-02-02 to 1885-02-02 | completed | S |
| Advance care planning conversation, about 20 minutes | 1885-10-19 to 1885-10-19 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1884-10-20 | Influenza vaccine, 1884-1885 season | completed | S |
| 1878-05-14 | Tdap vaccine | completed | S |
| 1885-01-12 | Pneumococcal conjugate vaccine PCV20, given at the home visit | completed | S |
| 1885-06-01 | Hepatitis B vaccine, CpG-adjuvanted (HepB-CpG), dose 1 of 2 | completed | S |
| 1885-10-19 | Hepatitis B vaccine, CpG-adjuvanted (HepB-CpG), dose 2 of 2 | completed | S |
| 1885-10-19 | Influenza vaccine, 1885-1886 season | completed | S |
| 1885-10-19 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| Late winter of 1848 | Lung congestion and cough; removed from her seminary for about a month | D (CLM-0002) |
| 1851 | Symptoms then thought to be consumptive, treated with a glycerine prescription for about two years until they subsided; no tuberculosis diagnosis is documented | D (CLM-0003) |
| 1863 to 1865 | Eye affliction with sensitivity to light and aching eyes, treated by a Boston ophthalmologist with dim light and no reading during two long stays in Cambridgeport; apparently cured. The diagnosis is not recorded (iritis most often proposed) | R (CLM-0004, CLM-0005, CLM-0006) |
| October 1883 | Nervous prostration after a death in her family, followed by continuing ill health | D (CLM-0010) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| Headaches, nausea, and tiredness for several months, worse in the mornings | active | S |
| Wants her care at home or by video, with as few trips to the clinic as possible | active | S |
Most recent measures: Sodium [Moles/volume] in Serum or Plasma 136 on 1885-04-20; Potassium [Moles/volume] in Serum or Plasma 5.3 on 1885-04-20; Carbon dioxide, total [Moles/volume] in Serum or Plasma 20 on 1885-04-20; Urea nitrogen [Mass/volume] in Serum or Plasma 34 on 1885-04-20; Creatinine [Mass/volume] in Serum or Plasma 1.66 on 1885-04-20; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1880)/1.73 sq M 36 on 1885-04-20; Glucose [Mass/volume] in Serum or Plasma 86 on 1885-04-20; Calcium [Mass/volume] in Serum or Plasma 9.4 on 1885-09-28; Phosphate [Mass/volume] in Serum or Plasma 3.6 on 1885-09-28; Parathyrin.intact [Mass/volume] in Serum or Plasma 61 on 1885-09-28; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 36 on 1885-09-28; Albumin [Mass/volume] in Serum or Plasma 4.1 on 1885-01-12; Hemoglobin [Mass/volume] in Blood 12.3 on 1885-01-12; Cholesterol [Mass/volume] in Serum or Plasma 214 on 1885-01-12; Cholesterol in HDL [Mass/volume] in Serum or Plasma 54 on 1885-01-12; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 134 on 1885-01-12; Triglyceride [Mass/volume] in Serum or Plasma 130 on 1885-01-12; Hemoglobin A1c/Hemoglobin.total in Blood 5.5 on 1885-01-12; Thyrotropin [Units/volume] in Serum or Plasma 2.1 on 1885-01-12; Albumin/Creatinine [Mass Ratio] in Urine 96 on 1885-09-28; Erythrocytes [#/area] in Urine sediment by Microscopy high power field 1 on 1885-01-12; Kidney failure 2-year risk [Likelihood] by KFRE 0.5 on 1885-01-12; Kidney failure 5-year risk [Likelihood] by KFRE 1.6 on 1885-01-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 1885-06-01; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 3 on 1885-10-19; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1885-10-19; Total score [AUDIT-C] 0 on 1885-10-19 [S]
Strengths and supports: Supports: her household, a few close friends she writes to often, and her work [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic kidney disease stage G3a A2, attributed to hypertension; synthetic modern diagnosis linked to the Bright's disease entered on her death certificate | active | confirmed | N18.31 | S — Synthetic modern diagnosis. Bright's disease as her recorded cause of death is documented (D); what it meant in her case is a retrospective question (R), and no kidney test from her lifetime exists. |
| Hypertension with chronic kidney disease (hypertensive chronic kidney disease, stage 3a); synthetic modern diagnosis linked to the retrospective view that she had severe hypertension | active | confirmed | I12.9 | S — Synthetic modern diagnosis; severe hypertension is a retrospective interpretation (R, possible), and no blood pressure from her lifetime exists. |
| Vitamin D deficiency with a mildly raised PTH in chronic kidney disease | active | confirmed | E55.9 | S — Synthetic laboratory finding at the intake visit. |
| Viral gastroenteritis with volume depletion and a prerenal rise in creatinine while taking losartan and dapagliflozin; resolved | resolved | confirmed | A08.4 | S — Synthetic illness at an unscheduled home visit, chosen to teach sick-day rules in chronic kidney disease; it does not echo any documented illness. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1885-01-12 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1885-01-12 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1885-01-12 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 | mmol/L | 22-29 mmol/L | Normal | S |
| 1885-01-12 | Urea nitrogen [Mass/volume] in Serum or Plasma | 21 | mg/dL | 6-21 mg/dL | Normal | S |
| 1885-01-12 | Creatinine [Mass/volume] in Serum or Plasma | 1.2 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 1885-01-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1880)/1.73 sq M | 54 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1885-01-12 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 1885-01-12 | Calcium [Mass/volume] in Serum or Plasma | 9.3 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1885-01-12 | Phosphate [Mass/volume] in Serum or Plasma | 3.8 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 1885-01-12 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 74 | pg/mL | 15-65 pg/mL | High | S |
| 1885-01-12 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 21 | ng/mL | 30-100 ng/mL | Low | S |
| 1885-01-12 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 1885-01-12 | Hemoglobin [Mass/volume] in Blood | 12.3 | g/dL | 12-15.5 g/dL | Normal | S |
| 1885-01-12 | Cholesterol [Mass/volume] in Serum or Plasma | 214 | mg/dL | <=199 mg/dL | High | S |
| 1885-01-12 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 54 | mg/dL | >=50 mg/dL | Normal | S |
| 1885-01-12 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 134 | mg/dL | <=99 mg/dL | High | S |
| 1885-01-12 | Triglyceride [Mass/volume] in Serum or Plasma | 130 | mg/dL | <=149 mg/dL | Normal | S |
| 1885-01-12 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | <=5.6% | Normal | S |
| 1885-01-12 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 1885-01-12 | Albumin/Creatinine [Mass Ratio] in Urine | 240 | mg/g | <=30 mg/g | High | S |
| 1885-01-12 | Erythrocytes [#/area] in Urine sediment by Microscopy high power field | 1 | /[HPF] | <=2 /[HPF] | Normal | S |
| 1885-01-12 | Kidney failure 2-year risk [Likelihood] by KFRE | 0.5 | % | S | ||
| 1885-01-12 | Kidney failure 5-year risk [Likelihood] by KFRE | 1.6 | % | S | ||
| 1885-01-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 1885-01-12 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 5 | {score} | S | ||
| 1885-02-02 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1885-02-02 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1885-02-02 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 | mmol/L | 22-29 mmol/L | Normal | S |
| 1885-02-02 | Urea nitrogen [Mass/volume] in Serum or Plasma | 22 | mg/dL | 6-21 mg/dL | High | S |
| 1885-02-02 | Creatinine [Mass/volume] in Serum or Plasma | 1.26 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 1885-02-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1880)/1.73 sq M | 51 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1885-02-02 | Glucose [Mass/volume] in Serum or Plasma | 90 | mg/dL | 70-99 mg/dL | Normal | S |
| 1885-02-02 | Albumin/Creatinine [Mass Ratio] in Urine | 262 | mg/g | <=30 mg/g | High | S |
| 1885-03-02 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1885-03-02 | Potassium [Moles/volume] in Serum or Plasma | 4.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1885-03-02 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 23 | mmol/L | 22-29 mmol/L | Normal | S |
| 1885-03-02 | Urea nitrogen [Mass/volume] in Serum or Plasma | 23 | mg/dL | 6-21 mg/dL | High | S |
| 1885-03-02 | Creatinine [Mass/volume] in Serum or Plasma | 1.32 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 1885-03-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1880)/1.73 sq M | 48 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1885-03-02 | Glucose [Mass/volume] in Serum or Plasma | 88 | mg/dL | 70-99 mg/dL | Normal | S |
| 1885-06-01 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1885-06-01 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1885-06-01 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 24 | mmol/L | 22-29 mmol/L | Normal | S |
| 1885-06-01 | Urea nitrogen [Mass/volume] in Serum or Plasma | 22 | mg/dL | 6-21 mg/dL | High | S |
| 1885-06-01 | Creatinine [Mass/volume] in Serum or Plasma | 1.3 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 1885-06-01 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1880)/1.73 sq M | 49 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1885-06-01 | Glucose [Mass/volume] in Serum or Plasma | 91 | mg/dL | 70-99 mg/dL | Normal | S |
| 1885-06-01 | Albumin/Creatinine [Mass Ratio] in Urine | 118 | mg/g | <=30 mg/g | High | S |
| 1885-06-01 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 1885-09-28 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1885-09-28 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1885-09-28 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 25 | mmol/L | 22-29 mmol/L | Normal | S |
| 1885-09-28 | Urea nitrogen [Mass/volume] in Serum or Plasma | 21 | mg/dL | 6-21 mg/dL | Normal | S |
| 1885-09-28 | Creatinine [Mass/volume] in Serum or Plasma | 1.28 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 1885-09-28 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1880)/1.73 sq M | 50 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1885-09-28 | Glucose [Mass/volume] in Serum or Plasma | 90 | mg/dL | 70-99 mg/dL | Normal | S |
| 1885-09-28 | Albumin/Creatinine [Mass Ratio] in Urine | 96 | mg/g | <=30 mg/g | High | S |
| 1885-09-28 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1885-09-28 | Phosphate [Mass/volume] in Serum or Plasma | 3.6 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 1885-09-28 | Parathyrin.intact [Mass/volume] in Serum or Plasma | 61 | pg/mL | 15-65 pg/mL | Normal | S |
| 1885-09-28 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 36 | ng/mL | 30-100 ng/mL | Normal | S |
| 1885-04-20 | Sodium [Moles/volume] in Serum or Plasma | 136 | mmol/L | 135-145 mmol/L | Normal | S |
| 1885-04-20 | Potassium [Moles/volume] in Serum or Plasma | 5.3 | mmol/L | 3.5-5.1 mmol/L | High | S |
| 1885-04-20 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 20 | mmol/L | 22-29 mmol/L | Low | S |
| 1885-04-20 | Urea nitrogen [Mass/volume] in Serum or Plasma | 34 | mg/dL | 6-21 mg/dL | High | S |
| 1885-04-20 | Creatinine [Mass/volume] in Serum or Plasma | 1.66 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 1885-04-20 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1880)/1.73 sq M | 36 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Low | S |
| 1885-04-20 | Glucose [Mass/volume] in Serum or Plasma | 86 | mg/dL | 70-99 mg/dL | Normal | S |
| 1885-10-19 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1885-10-19 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 3 | {score} | S | ||
| 1885-10-19 | Total score [AUDIT-C] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1885-01-12 | Body height | 163 | cm | S |
| 1885-01-12 | Body weight | 54 | kg | S |
| 1885-01-12 | Body mass index (BMI) [Ratio] | 20.3 | kg/m2 | S |
| 1885-01-12 | Systolic blood pressure | 166 | mm[Hg] | S |
| 1885-01-12 | Diastolic blood pressure | 98 | mm[Hg] | S |
| 1885-01-12 | Heart rate | 78 | /min | S |
| 1885-01-12 | Respiratory rate | 14 | /min | S |
| 1885-01-12 | Body temperature | 36.6 | Cel | S |
| 1885-01-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1885-02-02 | Body height | 163 | cm | S |
| 1885-02-02 | Body weight | 53.8 | kg | S |
| 1885-02-02 | Body mass index (BMI) [Ratio] | 20.2 | kg/m2 | S |
| 1885-02-02 | Systolic blood pressure | 148 | mm[Hg] | S |
| 1885-02-02 | Diastolic blood pressure | 88 | mm[Hg] | S |
| 1885-02-02 | Heart rate | 74 | /min | S |
| 1885-02-02 | Respiratory rate | 14 | /min | S |
| 1885-02-02 | Body temperature | 36.5 | Cel | S |
| 1885-02-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1885-03-02 | Body height | 163 | cm | S |
| 1885-03-02 | Body weight | 53.6 | kg | S |
| 1885-03-02 | Body mass index (BMI) [Ratio] | 20.2 | kg/m2 | S |
| 1885-03-02 | Systolic blood pressure | 136 | mm[Hg] | S |
| 1885-03-02 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 1885-03-02 | Heart rate | 72 | /min | S |
| 1885-03-02 | Respiratory rate | 14 | /min | S |
| 1885-03-02 | Body temperature | 36.6 | Cel | S |
| 1885-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1885-04-20 | Body height | 163 | cm | S |
| 1885-04-20 | Body weight | 51.9 | kg | S |
| 1885-04-20 | Body mass index (BMI) [Ratio] | 19.5 | kg/m2 | S |
| 1885-04-20 | Systolic blood pressure | 104 | mm[Hg] | S |
| 1885-04-20 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 1885-04-20 | Heart rate | 102 | /min | S |
| 1885-04-20 | Respiratory rate | 18 | /min | S |
| 1885-04-20 | Body temperature | 37.6 | Cel | S |
| 1885-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1885-06-01 | Body height | 163 | cm | S |
| 1885-06-01 | Body weight | 53.2 | kg | S |
| 1885-06-01 | Body mass index (BMI) [Ratio] | 20 | kg/m2 | S |
| 1885-06-01 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1885-06-01 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1885-06-01 | Heart rate | 70 | /min | S |
| 1885-06-01 | Respiratory rate | 14 | /min | S |
| 1885-06-01 | Body temperature | 36.6 | Cel | S |
| 1885-06-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1885-09-28 | Body height | 163 | cm | S |
| 1885-09-28 | Body weight | 53.4 | kg | S |
| 1885-09-28 | Body mass index (BMI) [Ratio] | 20.1 | kg/m2 | S |
| 1885-09-28 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1885-09-28 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1885-09-28 | Heart rate | 68 | /min | S |
| 1885-09-28 | Respiratory rate | 14 | /min | S |
| 1885-09-28 | Body temperature | 36.5 | Cel | S |
| 1885-09-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1885-10-19 | Body height | 163 | cm | S |
| 1885-10-19 | Body weight | 53.5 | kg | S |
| 1885-10-19 | Body mass index (BMI) [Ratio] | 20.1 | kg/m2 | S |
| 1885-10-19 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1885-10-19 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1885-10-19 | Heart rate | 70 | /min | S |
| 1885-10-19 | Respiratory rate | 14 | /min | S |
| 1885-10-19 | Body temperature | 36.6 | Cel | S |
| 1885-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1885-01-12 | Primary care home visit for headaches, nausea, and tiredness, with raised blood pressure and abnormal kidney tests | finished | S |
| 1885-02-02 | Three-week kidney and blood pressure review in the clinic, combined with nephrology consultation and kidney ultrasound on one trip | finished | S |
| 1885-03-02 | Video visit four weeks after the losartan increase and dapagliflozin start, with home vital signs and home blood tests | finished | S |
| 1885-04-20 | Same-day home sick visit for vomiting and diarrhea | finished | S |
| 1885-06-01 | Home visit for the three-month kidney and blood pressure review | finished | S |
| 1885-09-28 | Video visit for the six-month kidney review, with home vital signs and home blood tests | finished | S |
| 1885-10-19 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Start losartan 50 mg daily and raise it to the maximum dose of 100 mg for A2 albuminuria; check potassium and creatinine 2 to 4 weeks after each start or increase, accepting a creatinine rise of up to 30 percent | completed | GL-CMID-2026, GL-KDIGO-CKD-2024, GL-KDIGO-BP-2021 | S |
| If a second sample confirms a urine albumin-creatinine ratio of at least 200 mg/g, add an SGLT2 inhibitor (dapagliflozin 10 mg daily) after the nephrology review, and check potassium and creatinine 2 to 4 weeks later | completed | GL-CMID-2026, GL-KDIGO-CKD-2024 | S |
| Stop naproxen and avoid all NSAIDs; acetaminophen for headache; check kidney function before any iodinated contrast; adjust drug doses to eGFR | completed | GL-CMID-2026, GL-KDIGO-CKD-2024 | S |
| Nephrology consultation to confirm the cause of chronic kidney disease with albuminuria in a woman in her fifties and to advise on treatment and follow-up | completed | GL-CMID-2026, GL-KDIGO-CKD-2024 | S |
| Sick-day guidance: during vomiting, diarrhea, or poor fluid intake, pause losartan, dapagliflozin, and any other blood pressure medicine, drink fluids, call the clinic, and restart after 24 to 48 hours of normal eating and drinking | completed | GL-CMID-2026, GL-KDIGO-CKD-2024 | S |
| CMID kidney and blood pressure monitoring: blood pressure every visit with home readings; eGFR and urine albumin twice a year at G3a A2; a metabolic panel with each draw; calcium, phosphate, and PTH every 6 to 12 months; vitamin D at baseline; hemoglobin and KFRE yearly; one lipid panel and a statin; medication review every visit; vaccines reviewed yearly | completed | GL-CMID-2026, GL-KDIGO-CKD-2024, GL-ACC-HTN-2017 | S |
| Atorvastatin 20 mg daily; vitamin D3 1,000 units daily with recheck of 25-hydroxyvitamin D, calcium, phosphate, and PTH | completed | GL-CMID-2026, GL-KDIGO-CKD-2024 | S |
| Vaccines for chronic kidney disease: PCV20 now, a two-dose hepatitis B series, and yearly influenza and COVID-19 vaccines | completed | GL-CMID-2026, GL-KDIGO-CKD-2024, GL-CDC-IMZ-2026 | S |
| Home-centered care: home visits and video visits with her own validated blood pressure cuff, scale, thermometer, and pulse oximeter; mobile phlebotomy; clinic trips only for tests that need them, with several tasks booked on one quiet early appointment | completed | GL-CMID-2026, GL-KDIGO-CKD-2024 | S |
| PHQ-9 and GAD-7 at baseline and yearly; her long-standing wish for solitude is respected and not treated as a disorder unless symptoms cause distress or impairment | completed | GL-CMID-2026, GL-USPSTF-ANX-2023, GL-USPSTF-DEP-2023 | S |
| Sodium below 2 g a day, a plant-rich diet, and at least 150 minutes a week of activity, such as garden work and walking | completed | GL-CMID-2026, GL-KDIGO-CKD-2024, GL-ACC-HTN-2017 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Systolic blood pressure below 120 mmHg (KDIGO), and at least below 130/80, without lightheadedness | 1885-09-28 | completed | 118/74 mmHg on losartan 100 mg and amlodipine 5 mg | S |
| Urine albumin-creatinine ratio down by at least 30 percent from baseline on an ARB and an SGLT2 inhibitor | 1885-06-01 | completed | 118 mg/g at three months and 96 mg/g at six months, from 240 mg/g | S |
| Stable kidney function, with no fall in eGFR of more than 20 percent after the expected early dip | 1885-09-28 | active | eGFR 50 at the six-month review (54 at baseline); a temporary fall to 36 during gastroenteritis recovered | S |
| 25-hydroxyvitamin D of at least 30 ng/mL | 1885-09-28 | completed | 36 ng/mL on vitamin D3; PTH 61 pg/mL | S |
| Care delivered at home or by video wherever safe, with clinic trips limited to tests that need the clinic | 1885-09-28 | completed | Two clinic trips in the episode, each combining several tasks; all other visits at home or by video | S |